An isolated fully human monoclonal antibody, or fragment thereof, that binds IL-6/IL-6R complex (IL-6Rc), wherein said antibody comprises a variable heavy chain complementarity determining region 1 (VH CDR1), a variable heavy chain complementarity determining region 2 (VH CDR2), a variable heavy chain complementarity determining region 3 (VH CDR3), a variable light chain complementarity determining region 1 (VL CDR1), a variable light chain complementarity determining region 2 (VL CDR2), a variable light chain complementarity determining region 3 (VL CDR3) selected from the group consisting of: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 33, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 24, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 26; (b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 16, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 17, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 24, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 26; (c) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 18, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 19, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 20, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 28, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 29; and (d) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 21, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 22, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 23, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 31. (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 33, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 24, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 26; (b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 16, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 17, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 24, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 26; (c) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 18, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 19, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 20, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 28, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 29; and (d) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 21, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 22, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 23, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 25, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 31.